Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Technical Hurdles, Commercial Limits Complicate Supplement-To-Drug Moves

This article was originally published in The Tan Sheet

Executive Summary

Firms should investigate regulatory hurdles and gauge the commercial appeal of a finished product before moving dietary supplement ingredients into the pharmaceutical realm, say manufacturing and testing consultants
Advertisement

Related Content

FDA Guidance Raises Prospect Of More INDs For Supplement Research
FDA Guidance Raises Prospect Of More INDs For Supplement Research
FDA Guidance Raises Prospect Of More INDs For Supplement Research
Supplement-To-Drug Applications Look Like The Next Wave To Some Experts
Supplement-To-Drug Applications Look Like The Next Wave To Some Experts
GOED Casts Wider Membership Net As Omega-3 Applications Broaden
Ovos Plots Vivimind Cognitive Supplement Launch, Awaits FDA Reply
FDA Must Lift "Limbo" Over Trials In Supplement Development - Caucus
Congress Did Not Intend FDAAA Sec. 912 To Apply To Supplements – Industry
Congress Did Not Intend FDAAA Sec. 912 To Apply To Supplements – Industry

Topics

Advertisement
UsernamePublicRestriction

Register

PS104257

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel